BACKGROUND: Glucarpidase rapidly reduces methotrexate plasma concentrations in patients experiencing methotrexate-induced renal dysfunction. Debate exists regarding the role of glucarpidase in therapy given its high cost. The use of reduced-dose glucarpidase has been reported, and may allow more institutions to supply this drug to their patients. This report explores the relationship between glucarpidase dosage and patient outcomes in pediatric oncology patients. METHODS: The authors evaluated data from 26 patients who received glucarpidase after high-dose methotrexate. Decrease in plasma methotrexate concentrations and time to renal recovery were evaluated for an association with glucarpidase dosage, which ranged from 13 to 90 units/kg. RESULTS: No significant relationship was found between glucarpidase dosage (units/kg) and percent decrease in methotrexate plasma concentrations measured by TDx (P > 0.1) or HPLC (P > 0.5). Patients who received glucarpidase dosages <50 units/kg had a median percent reduction in methotrexate plasma concentration of 99.4% (range, 98-100) measured by HPLC compared to a median percent reduction of 99.4% (range, 77.2-100) in patients who received ≥50 units/kg. Time to SCr recovery was not related to glucarpidase dosage (P > 0.8). CONCLUSIONS: The efficacy of glucarpidase in the treatment of HDMTX-induced kidney injury was not dosage-dependent in this retrospective analysis of pediatric oncology patients.
BACKGROUND: Glucarpidase rapidly reduces methotrexate plasma concentrations in patients experiencing methotrexate-induced renal dysfunction. Debate exists regarding the role of glucarpidase in therapy given its high cost. The use of reduced-dose glucarpidase has been reported, and may allow more institutions to supply this drug to their patients. This report explores the relationship between glucarpidase dosage and patient outcomes in pediatric oncology patients. METHODS: The authors evaluated data from 26 patients who received glucarpidase after high-dose methotrexate. Decrease in plasma methotrexate concentrations and time to renal recovery were evaluated for an association with glucarpidase dosage, which ranged from 13 to 90 units/kg. RESULTS: No significant relationship was found between glucarpidase dosage (units/kg) and percent decrease in methotrexate plasma concentrations measured by TDx (P > 0.1) or HPLC (P > 0.5). Patients who received glucarpidase dosages <50 units/kg had a median percent reduction in methotrexate plasma concentration of 99.4% (range, 98-100) measured by HPLC compared to a median percent reduction of 99.4% (range, 77.2-100) in patients who received ≥50 units/kg. Time to SCr recovery was not related to glucarpidase dosage (P > 0.8). CONCLUSIONS: The efficacy of glucarpidase in the treatment of HDMTX-induced kidney injury was not dosage-dependent in this retrospective analysis of pediatric oncology patients.
Authors: Brigitte C Widemann; Frank M Balis; AeRang Kim; Matthew Boron; Nalini Jayaprakash; Aiman Shalabi; Michelle O'Brien; Michelle Eby; Diane E Cole; Robert F Murphy; Elizabeth Fox; Percy Ivy; Peter C Adamson Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: B C Widemann; F M Balis; R F Murphy; J M Sorensen; M J Montello; M O'Brien; P C Adamson Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: S Buchen; D Ngampolo; R G Melton; C Hasan; A Zoubek; G Henze; U Bode; G Fleischhack Journal: Br J Cancer Date: 2005-02-14 Impact factor: 7.640
Authors: Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood Journal: Clin J Am Soc Nephrol Date: 2022-03-02 Impact factor: 10.614
Authors: Lauren R Schaff; Mina Lobbous; Dean Carlow; Ryan Schofield; Igor T Gavrilovic; Alexandra M Miller; Jacqueline B Stone; Anna F Piotrowski; Ugur Sener; Anna Skakodub; Edward P Acosta; Kevin J Ryan; Ingo K Mellinghoff; Lisa M DeAngelis; Louis B Nabors; Christian Grommes Journal: BMC Cancer Date: 2022-01-13 Impact factor: 4.430
Authors: Laura B Ramsey; Frank M Balis; Maureen M O'Brien; Kjeld Schmiegelow; Jennifer L Pauley; Archie Bleyer; Brigitte C Widemann; David Askenazi; Sharon Bergeron; Anushree Shirali; Stefan Schwartz; Alexander A Vinks; Jesper Heldrup Journal: Oncologist Date: 2017-10-27
Authors: Ann Young; Daniel Beriault; Benjamin Jung; Anna Nikonova; Dory Abosh; Samantha Lee; Jeff Zaltzman; Jeffrey Perl Journal: Can J Kidney Health Dis Date: 2019-12-21